NCT06491927
Long Term Follow-up for RGX-202
Enrolling by Invitation
Not specifiedAll AgesObservationalREGENXBIO Inc.
~66 participants
Updated 2026-03-24 on ClinicalTrials.gov
What's tested:No Intervention
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluation of long-term safety of RGX-202
Measured over Baseline, 5 years inclusive of parent study
Conditions
Where it's being run
5 sites across 5 statesArkansas1
California1
Illinois1
Texas1
Virginia1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
The parent(s) or legal guardian(s) of the participant has/(have) provided written informed consent and (where applicable) Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been explained, prior to any research-related procedures; and, where applicable, the minor participant has provided written or verbal assent according to local requirements.
Must have undergone evaluation in a previous clinical study following a single IV infusion of RGX-202 for the treatment of DMD and either completed or withdrawn early from that study.
Participant and parent(s)/legal guardian(s) are willing and able to comply with scheduled visits, and study procedures.
Sexually active participants must be willing to use a medically accepted method of contraception from the time of the screening visit through 5 years after RGX-202 administration.
What this trial measures
- Evaluation of long-term safety of RGX-202Baseline, 5 years inclusive of parent study
Incidences of AEs and SAEs over time